Reuters logo
BRIEF-Clovis Oncology submits supplemental New Drug Application for rucaparib
October 9, 2017 / 8:21 PM / 12 days ago

BRIEF-Clovis Oncology submits supplemental New Drug Application for rucaparib

Oct 9 (Reuters) - Clovis Oncology Inc

* Clovis Oncology submits supplemental New Drug Application for rucaparib as maintenance treatment for patients with platinum-sensitive recurrent ovarian cancer

* Clovis Oncology Inc - ‍plans to file Marketing Authorization Application in Europe in early 2018 for maintenance treatment indication​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below